16 April 2012

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

 

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

---

About Starpharma

This document contains Forward Looking Statements

For Further Information

---